BSE Live
Jan 30, 16:01Prev. Close
1208.45
Open Price
1198.60
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 30, 15:59Prev. Close
1208.90
Open Price
1200.00
Bid Price (Qty.)
1218.10 (63)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Dr Reddys Laboratories (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| INCOME | |||
| Revenue From Operations [Gross] | 1,625.56 | 1,740.20 | |
| Less: Excise/Sevice Tax/Other Levies | 76.80 | 78.98 | |
| Revenue From Operations [Net] | 1,548.76 | 1,661.22 | |
| Total Operating Revenues | 1,548.76 | 1,661.22 | |
| Other Income | -8.41 | 32.52 | |
| Total Revenue | 1,540.35 | 1,693.73 | |
| EXPENSES | |||
| Cost Of Materials Consumed | 451.17 | 508.87 | |
| Purchase Of Stock-In Trade | 166.08 | 123.33 | |
| Operating And Direct Expenses | 47.43 | 42.42 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -29.62 | -9.66 | |
| Employee Benefit Expenses | 178.66 | 161.39 | |
| Finance Costs | 3.76 | 0.59 | |
| Depreciation And Amortisation Expenses | 92.46 | 71.72 | |
| Other Expenses | 580.81 | 491.73 | |
| Total Expenses | 1,495.99 | 1,390.39 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 44.36 | 303.34 | |
| Exceptional Items | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 44.36 | 303.34 | |
| Tax Expenses-Continued Operations | |||
| Current Tax | 0.00 | 20.24 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | |
| Deferred Tax | -21.10 | -0.09 | |
| Tax For Earlier Years | 0.00 | 0.00 | |
| Total Tax Expenses | -21.10 | 20.15 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 65.46 | 283.20 | |
| Profit/Loss From Continuing Operations | 65.46 | 283.20 | |
| Profit/Loss For The Period | 65.46 | 283.20 | |
| OTHER ADDITIONAL INFORMATION | |||
| EARNINGS PER SHARE | |||
| Basic EPS (Rs.) | 8.55 | 37.01 | |
| Diluted EPS (Rs.) | 8.55 | 37.01 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | |||
| Imported Raw Materials | 184.70 | 165.02 | |
| Indigenous Raw Materials | 153.17 | 238.46 | |
| STORES, SPARES AND LOOSE TOOLS | |||
| Imported Stores And Spares | 9.63 | 9.24 | |
| Indigenous Stores And Spares | 60.46 | 54.91 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | |||
| Equity Share Dividend | 38.26 | 38.26 | |
| Tax On Dividend | 5.37 | 4.90 | |
| Equity Dividend Rate (%) | 100.00 | 100.00 |
22.01.2026
Dr Reddys Labs Consolidated December 2025 Net Sales at Rs 8,753.40 crore, up 4.44% Y-o-Y
22.01.2026
Dr Reddys Labs Standalone December 2025 Net Sales at Rs 4,282.70 crore, down 14.6% Y-o-Y
22.01.2026
16.01.2026
22.01.2026
Dr Reddys Labs Consolidated December 2025 Net Sales at Rs 8,753.40 crore, up 4.44% Y-o-Y
22.01.2026
Dr Reddys Labs Standalone December 2025 Net Sales at Rs 4,282.70 crore, down 14.6% Y-o-Y
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz